Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6422109 | 0.98 | MAPT (0.59) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL8984382 | 0.98 | MAPT (0.59) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL1008067 | 0.98 | MAPT (0.59) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL830483 | 0.98 | MAPT (0.59) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL1007119 | 0.98 | MAPT (0.59) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL5508985 | 0.98 | MAPT (0.59) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL8984468 | 0.98 | MAPT (0.59) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL2871485 | 0.98 | MAPT (0.59) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL2867823 | 0.98 | MAPT (0.59) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL25801992 | 0.96 | MAPT (0.53) | MAPTRXFP1HDAC3MAPK1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060040366-A1 | New polyhydroxyalkanoate comprising unit having (phenylmethyl) oxy structure on side chain thereof, and method for producing the same | CANON KABUSHIKI KAISHA (JP) | 2006-02-23 | — | — | US | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260041785-A1 | POLYGLYCEROL-CONJUGATED LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME | GENERATION BIO CO (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | SERVIER LAB (FR) | 2026-01-01 | — | — | US | disclosed |
| EP-4626400-A1 | NOVEL POLYGLYCEROL-CONJUGATED LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME | Generation Bio Co. (US) | 2025-10-08 | — | — | EP | disclosed |
| WO-2025049064-A9 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | SIGNPATH PHARMA INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-4551566-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025090663-A1 | NOVEL POLYGLYCEROL-CONJUGATED LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME | GENERATION BIO CO. (US) | 2025-05-01 | — | — | WO | disclosed |
| CN-119816491-A | New spirocyclohexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2025-04-11 | — | — | CN | disclosed |
| WO-2025049064-A2 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | SIGNPATH PHARMA INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-5700799-A | MICROBIOCIDES FOR TREATING HUMAN OR ANIMAL DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-23 | — | — | US | disclosed |
| US-5547950-A | FOR TREATING DRUG RESISTANT STAPHYLOCOCCUS AND STREPTOCOCCUS INFECTIONS | THE UPJOHN COMPANY (US) | 1996-08-20 | — | — | US | disclosed |
| WO-1995006048-A1 | (3-PYRIDYL)TETRAFURAN-2-YL SUBSTITUTED CARBOXYLIC ACIDS | CIBA-GEIGY AG (CH) | 1995-03-02 | — | — | WO | disclosed |
| EP-0640077-A1 | OXAZOLIDINONES CONTAINING A SUBSTITUTED DIAZINE MOIETY AND THEIR USE AS ANTIMICROBIALS | PHARMACIA & UPJOHN COMPANY (US) | 1995-03-01 | — | — | EP | disclosed |
| US-5371096-A | (3-pyridyl)tetrafuran-2-yl substituted carboxylic acids | CIBA-GEIGY CORPORATION (US) | 1994-12-06 | — | — | US | disclosed |
| CN-1079964-A | The (oxazolidinon-5-yl-methyl)-2-thiophene-carboxamides antiseptic-germicide that contains the substituted diazine moieties base | UPJOHN CO (US) | 1993-12-29 | — | — | CN | disclosed |
| WO-1993023384-A1 | OXAZOLIDINONES CONTAINING A SUBSTITUTED DIAZINE MOIETY AND THEIR USE AS ANTIMICROBIALS | THE UPJOHN COMPANY (US) | 1993-11-25 | — | — | WO | disclosed |
| US-5036152-A | Antiinflammatory | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-07-30 | — | — | US | disclosed |
| US-4888328-A | Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids | HOESCHST-ROUSSEL INCORPORATED (US) | 1989-12-19 | — | — | US | disclosed |
| EP-0332129-A2 | Alkoxy- and alkylamino-carbonylalkylphospholipids, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BCL2A1, BAX | MAPT 4275/4885RXFP1 2949/4885HDAC3 142/4885 |
| US-20260041785-A1 | POLYGLYCEROL-CONJUGATED LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME | PCTP, PLTP, PHOSPHO1 | MAPT 1278/4885RXFP1 2642/4885HDAC3 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.